Fig. 2.
Effects of the EP4 antagonist ONO-AE3-208 on EAE development. ONO-AE3-208 was administered per os at 10 mg/kg per day to WT C57BL/6 mice from days −1 to 25, days −1 to 7, or days 7 to 25. Control mice received vehicle. Data for clinical score are means ± SEM for six mice per group. *P < 0.05 vs. the corresponding value for control mice.